Skip to main content
Equibles
MLTX logo

MLTX · MoonLake Immunotherapeutics

Track MLTX — free

Use MLTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.39 +0.04 (+0.32%) At close · Sep 18
Rebalance outlook locked
Market Cap
$1.05B
Shares
85.11M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.39 Open$12.28 Day$12.09–12.50 52W close$6.25–61.99 Avg vol 30d1.6M Short int7.1M · 8.4% float · 6.7d Short vol19% Last earningsFeb 23, 2026 DataOct 2020–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$263.05M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.8%
Year over year · more shares
Price change (1Y)
-77.1%
Trailing year
Short interest
8.4%
Latest settlement · 6.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −27%
below
Price vs 50-day avg −26%
below
RSI (14) 25
oversold
MACD trend Negative
52-week position 11%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −22%
trailing
6-month return −28%
trailing
YTD return −6%
this year
Relative strength −49%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $17 › 200d $17 — 200d above 50d
Institutional flow Accumulating
+17% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.39% of float · ▲ +4.8% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
175 holders — near 3-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Weak
EPS growth −87%
Y/Y
Free cash flow $-196.0M
Balance sheet $260.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 118%
annualized · 1-yr
Max drawdown −90%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
5 · 2 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−27% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
25 Neutral
MACD trend
Negative Bearish
52-week position
11% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) Death cross
50d $17 › 200d $17 — 200d above 50d
Institutional flow Accumulating
+17% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.39% of float · ▲ +4.8% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
175 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $12 · 11% Range high $62
vs 200-day avg -27% vs 50-day avg -26% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MLTX
MoonLake Immunotherapeutics
this stock
$1.05B -6.0% — — 8.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.06B +12.1% +46.2% 29.9 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.80B +1.7% +20.8% 19.4 2.5%
MRNA
Moderna, Inc.
 $61.50B +422.3% +4.3% — 9.8%
ARGX
Argenx SE
 $60.93B +17.8% — — 2.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
175
% held
88.4%
Net QoQ
+10.2M sh
Top holder
BVF INC/IL
Held Float
View
Held by Funds
Fund positions
56
View
Short & Settlement
Short Interest Rising
Shares short
7.1M
Days to cover
6.7d
Change
+325.4K sh
View
Short Volume
Short vol %
19%
As of
Sep 18, 2026
Short Total
View
Fails to Deliver
FTD shares
444
Value
$6.7K
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
46.1%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-227.3M
EPS diluted
$-3.53
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
13
View
Proposed Sales
Value
$2.9M
Shares
150.0K
Filed
Jul 15, 2026
View
Earnings & Events
Earnings Calls Upcoming
Next call
Nov 10, 2026
Last call
Sep 16, 2026
View
Investor Relations
Upcoming events
6
View

Performance

5D 20D 120D MTD YTD
MLTX -1.0% -21.9% -28.5% -17.7% -6.0%
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY -0.6% -21.8% -48.6% -17.0% -17.7%
Key facts CIK 1821586 CUSIP 61559X104 13F (30d) 6 filings 6 filers Visit website Investor relations